Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) is a highly chemoresistant and metastatic disease with a dismal 5-year survival rate of 6%. More effective therapeutic targets and approaches are urgently needed to tackle this devastating disease. The base excision repair (BER) pathway has been identified as a predictor of therapeutic response, prognostic factor, and therapeutic target in a variety of cancers. This review will discuss our current understanding of BER in PDA and its potential to improve PDA treatment.

SUBMITTER: Sharbeen G 

PROVIDER: S-EPMC4428371 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature